Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428525 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07428525 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 36 participants.
The verdict
NCT07428525, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
Interventions
- DRUG AMG 133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07428525
The ClinicalTrials.gov registry entry for NCT07428525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 133 is the first listed.
NCT07428525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07428525 about?
NCT07428525 is a clinical study titled "A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function". The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
What is the current status of trial NCT07428525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-03-14. Estimated completion is 2026-02-26.
What interventions are being tested in trial NCT07428525?
The interventions under investigation include: AMG 133 (DRUG).
Who is sponsoring clinical trial NCT07428525?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.